FAIRFIELD, Conn., April 12, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) announced today that it will hold a conference for the medical community on May 17, 2010, in Boston, Mass. at the Marriott Long Wharf Hotel from 9:00 a.m. to 3:30 p.m., to introduce CTT's Calmare® pain therapy to the medical community. Professor Giuseppe Marineo, MD, DSc., Researcher, Founding President of Delta Research and Development, Tor Vergata University of Rome, is the Italian inventor of the "Scrambler Therapy," the technology used in the Calmare medical device. Prof. Marineo will be honored by CTT at the conference and he will present the scientific basis for this revolutionary pain treatment method. Throughout the day, several physicians will present patient case studies stemming from their use of this innovative technology to treat various types of chronic pain including severe pain from cancer and chemotherapy-induced peripheral neuropathy (CIPN), failed back surgery, phantom limb syndrome, as well as pain from shingles and a variety of other maladies. Typically, the patients' pain has been resistant to other treatment methodologies, including powerful narcotic painkillers that have been linked to adverse side effects.
The physicians presenting their patient case studies will include:
- Perry Rosenthal, MD - Founding President, Vice Chairman and Scientific Director at the Boston Foundation for Sight, and Assistant Clinical Professor of Ophthalmology, Harvard Medical School
- Salahadin Abdi, MD - Professor and Chief, University of Miami Pain Center, Anesthesiology, Perioperative Medicine & Pain Management
- Toby Campbell, MD - Assistant Professor of Medicine, Hematology & Oncology, University of Wisconsin, Paul J. Carbone Cancer Center
- Stephen J. D'Amato, MD, FACEP- Medical Director, Calmar Pain Relief Therapy, Clinical Assistant Professor of Medicine, Boston University School of Medicine, and Medical Staff, Roger Williams Medical Center.
"We are pleased to be able to highlight our Calmare pain therapy medical device to physicians at this upcoming event," said John B. Nano, CTT's Chairman, President and CEO. "Having Prof. Marineo discuss his development of this technology will provide a unique perspective for physicians wanting to gain a deeper understanding of how the device functions as well as its safety and efficacy in relieving patients' pain. We are fortunate that on his first U.S visit from his research facility in Italy he is presenting to members of the medical community."
With recent media coverage focusing on the negative side effects of morphine and other powerful painkillers, the Calmare device offers physicians an effective alternative for treating high intensity oncologic and neuropathic pain, including pain resistant to opioids and other treatment methodologies. Physicians interested in attending the conference should contact Kim Thompson of Competitive Technologies at 203.331.4817 or kthompson@competitivetech.net.
For more information about the device visit: www.CalmareTT.com.
About Competitive Technologies, Inc.
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers and matching those requirements with commercially viable product or technology solutions. CTT is a global leader in identifying, developing and commercializing innovative products and technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders. Visit CTT's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2009, filed with the SEC on October 27, 2009, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.